Proprietary TRPV6-targeting peptide platform enables highly targeted treatments for several solid tumor cancers
Our Science
Our discovery of a toxin in the saliva of the venomous northern short-tailed shrew has led to the creation and continued development of a new class of targeted cancer treatments.
Partner with us
We are seeking development and commercialization partners for SOR-C13. We are also seeking partnerships / research collaborations for our peptide-drug conjugate platform.
Invest
We are a private oncology-focused company with multiple assets in clinical and preclinical development approaching near-term inflection points. Contact us to learn about current investment opportunities for accredited investors.
Address
18 Botsford St., Suite 201
Moncton, N.B. E1C 4W7
Canada
T: 506.856.0400
F: 506.856.0414
E: info@soricimed.com
© Copyright 2023 Soricimed Biopharma